Bestop Medical Completes Multi-Million RMB Angel Funding Round to Advance Integrated Single-Cell Diagnostics Solutions

Recently, Tianjin BioAurora Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “BioAurora Pharma”) announced that it had completed an angel financing round worth several million yuan in January 2021, with exclusive investment from Shanghai Qingfeng Capital.This round of financing will propel the company to complete the establishment of a single-cell diagnostic instrument and reagent translation platform, as well as the construction of its technical analysis system.

Tianjin BioAto Medicine Technology Co., Ltd. was founded by a team of senior scientists specializing in single-cell high-throughput sequencing technology. Committed to building China’s leading brand for single-cell tumor diagnostics, the company provides comprehensive solutions—including single-cell diagnostic instruments, diagnostic reagents, and medical diagnostic technology analysis—for both research and clinical applications, thereby enhancing the efficiency of personalized tumor diagnosis and treatment.

In the field of biomedical testing, the continuous improvement of detection accuracy is an inevitable trend.Single-cell detection technologies represent a fundamental advancement over previous methods in characterizing cellular-level differences, offering unprecedented resolution and precision in cell clone identification, differential expression profiling, and cell population characterization. These technologies are particularly well-suited for assessing tumor cell heterogeneity and immune system diversity.

The medical community has long recognized the existence of tumor heterogeneity and has conducted extensive research on its impact on clinical cancer treatment. However, for a long time, there has been no effective, user-friendly, and cost-effective detection technology available. Tumor heterogeneity exists not only between different individuals (patients) but also within the same tumor in a single individual. It refers to the differences from genotype to phenotype among different patients or across different regions of the same patient’s tumor. These differences include variations in DNA base mutation profiles among tumor cells, chromosomal ploidy (number) differences, disparities in gene expression, and variations in the degree of differentiation, among others. Furthermore, cells from tumor tissues at different clinical stages exhibit high diversity in their evolutionary trajectories.

Tumor heterogeneity is one of the greatest obstacles in the clinical diagnosis and treatment of cancer, with refractoriness and post-treatment recurrence being directly linked to this heterogeneity. Current clinical detection technologies are still unable to achieve high-throughput molecular profiling at single-cell resolution.High-throughput single-cell molecular detection holds immense technical potential for identifying tumor cell heterogeneity, with the possibility of fundamentally addressing the challenges in heterogeneity assessment.Test results can assist in determining clinical treatment plans, enabling personalized precision diagnosis and precision therapy, improving treatment efficacy, enhancing prognosis, and extending patient survival.BioAim Pharmaceuticals aims to address the challenge of tumor heterogeneity from a diagnostic perspective, by providing society with effective, cost-efficient, and user-friendly molecular diagnostic products featuring single-cell resolution.

BioAlliance Pharma is headquartered in the Binhai New Area of Tianjin, with a research and development service center established in Beijing.The management and technical teams possess extensive experience in service delivery and R&D within the single-cell field, having successfully led the establishment of China’s earliest and most experienced single-cell research service team.The company has established in-depth collaborations with internationally leading single-cell platform providers such as 10X Genomics, BD, and Mission Bio, demonstrating a profound understanding of single-cell detection technologies, products, and applications. It boasts a well-structured team, a comprehensive R&D service platform, and fully equipped laboratory facilities. Its corporate philosophy and strategic planning have gained investor recognition, enabling it to successfully complete its angel financing round in the second month after establishment. Moving forward, BaiAo Medicine will provide integrated technical solutions encompassing single-cell diagnostic instruments, diagnostic reagents, and medical diagnostic technology analysis, with the core objective of enhancing the efficacy of personalized tumor diagnosis and treatment.

BioAio is committed to advancing and promoting the application of high-throughput single-cell detection technologies in the medical field. Upholding technological advancement as its path to growth, social responsibility as its duty, integrity-based collaboration for mutual success, and efficiency, focus, and reliable quality as its core competencies, BioAio strives to become a leading provider of advanced single-cell molecular detection systems.

Qingfeng Capital is an investment platform co-founded by multiple executives of listed companies. Its early partners are experts from diverse fields, including overseas-educated scientists, executives of listed companies, and angel investors. The firm is dedicated to value investing in, empowering, and growing with startups that possess strong technological attributes and significant potential industrial influence in sectors such as pharmaceuticals and healthcare, intelligent manufacturing, and new energy.